Journal
JOURNAL OF VIROLOGY
Volume 75, Issue 22, Pages 11079-11087Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.75.22.11079-11087.2001
Keywords
-
Categories
Funding
- NIAID NIH HHS [AI24345, AI-01469] Funding Source: Medline
- NICHD NIH HHS [HD27757] Funding Source: Medline
Ask authors/readers for more resources
Foreign glycoproteins expressed in recombinant vesicular stomatitis virus (VSV) can elicit specific and protective immunity in the mouse model. We have previously demonstrated the expression of respiratory syncytial virus (RSV) G (attachment) and F (fusion) glycoprotein genes in recombinant VSV. In this study, we demonstrate the expression of RSV F and G glycoproteins in attenuated, nonpropagating VSVs which lack the VSV G gene (VSV DeltaG) and the incorporation of these RSV proteins into recombinant virions. We also show that intranasal vaccination of mice with nondefective VSV recombinants expressing RSV G (VSV-RSV G) or RSV F (VSV-RSV F) elicited RSV-specific antibodies in serum (by enzyme-linked immunosorbent assay [ELISA]) as well as neutralizing antibodies to RSV and afford complete protection against RSV challenge. In contrast, VSV DeltaG-RSV F induced detectable serum antibodies to RSV by ELISA, but no detectable neutralizing antibodies, yet it still protected from RSV challenge. VSV DeltaG-RSV G failed to induce any detectable serum (by ELISA) or neutralizing antibodies and failed to protect from RSV challenge. The attenuated, nonpropagating VSV DeltaG-RSV F is a particularly attractive candidate for a live attenuated recombinant RSV vaccine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available